Neuronano AB was founded in 2006 by Prof. Jens Schouenborg and Investor Per-Anders Johansson with the vision to create a patent portfolio of bio-friendly, implantable electrode technology as well as commercial products that can improve life for people, primarily with Parkinson’s disease. Following groundbreaking research and development both within the company and in collaboration with the Neuronano Research Center (NRC), the company now has product concepts that are being tested in the preclinical phase. There is an enormous potential for this technology to be used very broadly and to treat multiple diseases and conditions.